FDA won't DQ doc over data submissions; Basilea gives isavuconazole update

@FierceBiotech: Acceleron inks $498M pact with Shire for lead muscle drug. Article  Follow @FierceBiotech

 @JohnCFierce:New leak from BLMB: Genzyme investors demanding $75 from Sanofi. Absolutely, positively, lowest possible bid. Sure.  Article | Follow @JohnCFierce 

> Federal regulators decided not to disqualify a prominent North Side HIV doctor whose clinic submitted fictitious data in a drug trial. News

> Basilea Pharmaceutica announced today that, in agreement with its partner Astellas, the initiation of study centers in the isavuconazole Phase III clinical program will be deferred to year-end or early 2011. Availability of Phase III data continues to be anticipated by 2013. Basilea release

> Bristol-Myers Squibb Company is commencing today, through its wholly owned subsidiary Zeus Acquisition Corporation, a cash tender offer to purchase all outstanding shares of common stock of ZymoGenetics. Bristol-Myers Squibb announced on Tuesday its intent to acquire ZymoGenetics. BMS release

> The hedge funds think Arena Pharmaceuticals will fail. That's the consensus opinion emerging from an informal email poll taken this week, which asked healthcare buy-side investors, mostly biotech-focused hedge funds, to handicap the Sept. 16 FDA advisory panel that will review Arena's obesity drug lorcaserin. Article

> With regulations covering biosimilar medicines falling into place around the world, there is a need to reach global agreement on criteria and guidelines for such products, say European generics industry leaders. Item

> The US-India Business Council will embark on a life sciences executive mission to coincide with the Biotechnology Industry Organisation's first annual international partnering conference in Hyderabad Sep 21-22. Story

> The pharmaceutical, biotech and medical device industries stand to benefit from President Obama's proposal to expand the research and development tax credit, according to Wall Street analysts. News

> Eurand has announced the resignation of CFO Mario Crovetto, effective January 2011. Eurand release

> Edimer Pharmaceuticals and CMC Biologics have executed a manufacturing contract to support the development of EDI200, a clinical-stage recombinant protein for the treatment of X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare genetic disease with orphan designation in the USA and Europe. Edimer/CMC release

And Finally... Antimicrobial peptides from the skin of frogs may protect against life-threatening, multidrug-resistant infections such as Pseudomonas aeruginosa say researchers from Italy. They detail their findings in the September 2010 issue of the journal Antimicrobial Agents and Chemotherapy. Release